1.18–5.24; p = 0.01) is in agreement with the observation that patients with plasma cell dyscrasia, especially those treated with anti-CD38 agents, are at high risk for breakthrough infections due to underlying immune deficiency from the disease itself and a suboptimal antibody response following vaccination [25,26]. This evidence concerns the gene CD38 and plasma cell neoplasm.